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Recent developments in monoclonal antibody production have brought about a rapid change: competitive-binding assays are being replaced by immunometric assays to measure hormones. Especially, assays of thyrotropin (TSH) are now predominantly based on immunometric principles and show improved sensitivity (1) (2) (3) (4) .
With assays involving
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Received October 20, 1986; acceptedDecember 24, 1986. total incubation times of less than 3 h, the concentrations of thyrotropin circulating in euthyroid subjects can be differentiated from the lesser concentrations circulating in thyrotoxic patients. With these assays, measurement of the basal (unstimulated) concentration of TSH will predict the responseof a thyroliberin-stimulation test (5); consequently, a single measurement of TSH, supplemented with assays of free thyroxin (Fl'4) and free triiodothyronine (FFs), has been proposed as the preferred strategy for testing thyroid function (6). However, this approach will be valid only if the thyrotropin concentration in most hospital patients without thyroid disease is within the same range of values found in healthy, euthyroid subjects. We have previously reported the development of a twosite assay for TSH that differentiates thyrotoxic patients from normal subjects (7). We describe here our experience with this assay with a larger population of normal subjects, patients with nonthyroidalillness, and a group of patients taking various drugs.
Subjects and Methods
Subjects. We studied patients admitted to the University Hospital of Wales with severe illness, either chronic liver disease, chronic renal failure, myocardial infarction, or cerebrovascular accident. They were not admitted for investigation of any thyroid disorder and were selected only if they had no pre-existing thyroid disease or family history of thyroid disease. All patients were examined by one of us (P.E.E.) and were judged to have no goiter and to be nil dlmn n n 1 Among these were 17 men and eight women (ages 21-72 years, mean age 55) with chronic liver disease-either primary biliary cirrhosis, chronic active hepatitis, or alcoholic cirrhosis; 13 men and 15 women (ages 18-73 years, mean 43) with chronic renal failure; 16 men and five women (ages 36-79 years, mean 63) with myocardial infarction; and 10 men and nine women (ages 52-86 years, mean 69) who had had a cerebrovascular accident.
In addition, we studied patients taking various drugs that are known or thought to affect results of thyroid-function tests. These included eight men and 12 women (ages 19-73 years, mean 48) taking heparin; from the epilepsy clinic, nine men and 11 women (ages 18-73 years, mean 42) who were taking phenytoin (mean dosage 355 mg/day, range 150-650); nine men and 11 women (ages 17-50 years, mean 29) who were taking sodium valproate (mean dosage 570 mg/day, range 400-800); and six men and 14 women (ages 17-65 years, mean 33) who were taking carbamazepine (mean dosage 760 mg/day, range 400-1200).
The control group consisted of 65 men and 69 women (ages 21-90 years, mean 63) who were visitors or outpatients to the hospital; they were clinically euthyroid with no personal or familyhistory of thyroid disease.
Methods. Blood was sampled in the morning from all subjects. The serum was separated and kept at -20 #{176}C until assayed. We measured TSH in serum by a previously described immunoradiometric assay involving a mixture of two 'I-1abeled monoclonal antibodies and a polyclonal antibody (raised in sheep) coupled to aminocellulose. The precision of the assay (CV) was 10% over the range 0. 
Results
Control subjects. Basal TSH concentrations in the 134 control subjects ranged from "undetectable" to 9.6 milli-int. units/L (mean 1.7, SD 1.5) (Figure 1) . Using this assay, we had previously (7) been able to distinguish thyrotoxic patients (TSH <0.2 milli-int. unit/L) from normal subjects (TSH range 0.4-3.6 milli-int. unitsfL). In this larger series of 134 apparently euthyroid subjects, seven (5.2%) had TSH concentrations <0.4 mifli-int. unitfL, and 10 (7.4%) had TSH concentrations >3.6 milli-int. unitsfL. These TSH values were skewed towards higher values and overlapped into the thyrotoxic range. We therefore combined the results from our previous study and used as our reference interval the TSH concentrations of 0.36 to 5.4 milli-int. unitsfL (median 1.49). Only one subject with normal concentrations of free thyroid hormones showed an undetectable concentration of TSH. Five subjects (2.3%) with normal concentrations of free thyroid hormones had TSH concentrations >5.4 mull-mt. unitsfL. The reference intervals, calculated as 2 SD from the mean for the free thyroid hormones, were as follows: Fl'4 10-26 pmol/L (mean 18.5, range 6.1-27.7); Fr3, Patients with nonthyroidal illness. For the 25 patients with chronic liver disease, the mean TSH was 2.3 milli-int. umtsfL, all but one result being within the normal range (Figure 2) . The mean FF4 for this group was 12.7 pmoL'L (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ) and the mean FF3 was 3.7 pmol/L (1.2-7.9). The mean TSH in 28 patients with chronic renal failure was 1.9 milli-int.
units/L, all the TSH concentrations being within the reference range. For this group, the mean FF4 Of these 80 patients receiving drugs, three (3.8%) had TSH concentrations outside the reference interval, five (6.3%) had Fr4 concentrations below the reference interval, and 10 (12.5%) had Fr3 concentrations both above and below the reference interval.
DiscussIon
Measurement of the TSH concentration in serum by a sensitive imniunoradiometric assay has been proposed as the initial screening test for evaluation of thyroid disorders. These studies have usually been done in specialized endocrine units to which patients with a high suspicion of thyroid disease are referred. In most clinical chemistry laboratories a large proportion of the workload comes from patients in whom the suspicion of thyroid disease is much lower, and thyroid dysfunction needs to be excluded. Thyroid-function tests may be required for patients with various acute or chronic illnesses, or who are receiving certain drugs. In these patients, the usual symptoms of thyroid disease may be masked by their illness, or by the drugs they are taking. In many instances thyroid-function tests are requested to exclude the presence of thyroid disease. For these patients, to minimize the number of investigations carried out and to be cost effective it would be preferable if a single test could reliably indicate the patient's thyroid status, uninfluenced by the illness or drug regime.
In our patients, TSH was clearly the test that predicted their euthyroid status better than did their free thyroid hormone concentration. Only six of 173 patients (3.5%) had TSH concentrations outside the reference interval; one patient had a TSH concentration of 0.1 milli-int. unitfL. Twenty-four patients (13.9%) had abnormally low Fr4 concentrations and 44 patients (25.4%) had abnormally low Fl'3 concentrations. The high TSH concentrations seen in four patients were not associated with the lowest Fr4 concentrations, but their FF4 concentrations were within the same range as that for the control euthyroid population. Possibly these increased serum TSH concentrations represent a group of subjects with subclinical hypothyroidism, although all subjects in the control group had normal Fr4 concentrations and the patient group also had normal or only slightly decreased Fl'4 concentrations as compared with the mean Fr4 concentration for their group. A normal response to thyroliberin would exclude the possibility of compensated hypothyroidism, although thyroliberin testing was not done in this study. concentrations as measured by the analog technique in clinically euthyroid patients with severe nonthyroidal illnesses reportedly are lowered (8, 9) and this decrease is ascribed to their lower serum albumin concentrations and abnormal concentrations of anions with high affinity for albumin (10). However, in a study in patients with different systemic illnesses, total T4 concentrations fell within the hypothyroid range so that the free-T4 index was lowered in 38% of patients with liver disease and 59% of patients with chronic renal failure (11). Whatever the mechanism responsible for the apparent lowering of FF4 concentrations, whether physiological or attributable to methodological factors, in all our nonthyroidally ill patients, if we use our laboratory reference range for FF4 of 8-26 pmolIL, only 10(5.8%) of the patients' results would overlap into the hypothyroid range.
Recently it has been proposed that the low thyroxin state that is associated with severe nonthyroidal illness may result from several events, one of which is a failure of the normal negative feedback control of the thyroid-pituitary axis, resulting in a decreased secretion of thyrotropin In patients with hematopoietic cancer or aplastic anemia, TSH concentrations decreased and became subnormal or undetectable (<0.33 milli-int. unit/L). If these results are confirmed with some of the other sensitive TSH assays now available, it would limit the usefulness of TSH in predicting the euthyroid status of these patients.
In our own series of patients who were not as critically ill as these patients, their TSH concentrations were not suppressed below those values found for euthyroid subjects. Of the patients on drugs, one patient who was on heparin had a suppressed concentration of TSH (0.1 milli-int. units/L), which overlapped with the thyrotoxic range.
We have confirmed here that in most patients who are clinically euthyroid but who have any of several different illnesses or are receiving various drugs, a basal TSH concentration will indicate their thyroid status.
